Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Dedicated to enhancing knowledge and skill in the care of the allergic patient."

ADVOCACY UPDATES

Brief Update on the Final CY 2019 Physician Fee Schedule

On November 1, the Centers for Medicare and Medicaid Services released the final Physician Fee…

read more

FDA Revised Draft Insanitary Conditions Guidance

The Food and Drug Administration (FDA) states, in a revised draft guidance released this week, that…

read more

Allergy Comments on 2019 Proposed PFS

The Advocacy Council of the American College of Allergy, Asthma and Immunology (ACAAI) together with its…

read more

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

02/15/19: Call For Proposals Deadline
Learn more

04/01/19: Fellow Exam Application Deadline
Learn more

06/01/19: Research Grant Cycle
Learn more

06/7/19: Membership Application Deadline to be eligible for AAOA Member rate for the 2019 Basic Course

07/31/19: Membership Application Deadline to be voted in at the 2019 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2019 Annual Meeting
Learn more

12/01/19: Research Grant Cycle
Learn more

EDUCATION

Be a Part of the 2019 AAOA Annual Meeting!

AAOA is accepting Scientific Abstracts for in-person oral or poster presentation at the 2019 AAOA Annual Meeting in New Orleans, LA - September 13-15, 2019. Submit Scientific Abstract 

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2019 Basic Course in Allergy & Immunology
June 27-29 | Minneapolis, MN
Learn More and Register

2019 AAOA Annual Meeting
September 13-15 | New Orleans, LA
Save the Date

2019 Advanced Course in Allergy & Immunology
December 12-14 | Austin, TX
Save the Date

AAOA Clinical Insights
Learn More and Register

PATIENT CORNER

History of Allergy Treatment

The history of modern allergy treatment dates back to the early decades of the twentieth century with the demonstration of decreased response to grass pollens following conjunctival challenge done by Noon and Freeman.

Read More

News and Updates

From the AAOA President, Matthew Ryan, MD

...the AAOA continues to be the organization that Otolaryngologists look to for up-to-date education and information on the…

read more

FDA Approves First Generic Version of EpiPen

The Food and Drug Administration approves the first generic version of EpiPen and EpiPen Jr.…

read more

Social and Networking Events at the 2018 AAOA Annual Meeting

This year’s Annual Meeting assures to be not only educational, interactive, and practice-centered, but also…

read more

Menu

A Brief History of Allergy Treatment

The history of modern allergy treatment dates back to the early decades of the twentieth century with the demonstration of decreased response to grass pollens following conjunctival challenge done by Noon and Freeman.  These techniques were subsequently modified that led to the development of subcutaneous introduction of allergens or subcutaneous immunothearpy (SCIT). Sublingual immunotherapy was first pioneered in the 1940s. In 2014, the FDA approved commercially prepared sublingual therapies for grass and ragweed.

Antihistamines were developed in the 1930s and became clinically available in the 1940s.  Second generations antihistamines were approved in mid-1980s providing relief of symptoms with decreased central nervous system side effects.

Corticosteroid nasal sprays were reportedly used as early as 1950s but did not gain prominent use until the 1970s with later generations improving patient tolerance and reducing impact on hypothalamic-pituitary axis.  In 2012 the release of a coformulated nasal spray with antihistamine and corticosteroid offered even greater efficacy.

Leukotrienes were discovered in the 1970s.   The discovery and introduction of Montelukast (Singulair) a decade later providing additional pharmacological management of inflammatory mediators.  

The most recent therapeutic introductions for allergy include monoclonal antibodies that are produced using recombinant DNA techniques.  These medications block IgE and various leukotrienes to eliminate or significantly ameliorate the inflammatory reaction.

__________________________________________________

References

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651049/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4761089/
https://www.jacionline.org/article/S0091-6749(10)01853-1/pdf

Allergies for the Otolaryngologist; Ferguson,B.J. and Golla,S;l Otolaryngologic Clinics of North America; June 2011; Volume 44; Number 3

http://www.allergiesexplained.com/pages/Desensitisation%20or%20Immuno%20Therapy.htm